Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A dec exp |
| Therapy | Molibresib |
| Indication/Tumor Type | ovarian clear cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A dec exp | ovarian clear cell carcinoma | predicted - sensitive | Molibresib | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Molibresib (GSK525762) in ovarian clear cell carcinoma cell lines in culture (PMID: 29760405). | 29760405 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29760405) | ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. | Full reference... |